tbuckley/cabot-search huggingface dataset:
Clinical utility of CT and FDG PET/CT in assessing the neck in node-positive head and neck cancer after chemoradiotherapy.
Authors: Susumu Nakahara, Yukinori Takenaka, Yoshifumi Yamamoto, Toshimichi Yasui, Atsushi Hanamoto, Hidenori Inohara
Journal: Journal of Clinical Oncology (2013)

6082 Background: Concurrent chemoradiotherapy has been widely accepted to treat locoregional advanced head and neck cancer, but the need for subsequent neck dissection remains controversial. Our objective was to determine whether CT or fluorodeoxyglucose (FDG) PET/CT is superior in the evaluation of persistent nodal disease after chemoradiotherapy in patients with node-positive head and neck squamous cell carcinoma (HNSCC). Methods: Study entry criteria included node-positive HNSCC treated with concurrent chemoradiotherapy, a local complete response, and post-treatment CT and FDG PET/CT studies 11 weeks after chemoradiotherapy. Fifty-eight patients with 68 node-positive necks were eligible. Nodes larger than 1 cm (minor axis), or with central necrosis on CT, or any visually hypermetabolic nodes on FDG PET/CT were considered clinically positive. Regardless of PET/CT findings, necks with positive CT were subjected to neck dissection, whereas those with negative CT were observed without neck dissection. Results: Seventeen necks showed positive CT, 13 and 4 of which underwent neck dissection and fine needle aspiration cytology, respectively, resulting in pathologic evidence of persistent nodal disease in 5 necks. Four of 51 necks with negative CT developed regional recurrence. Diagnostic accuracy of CT and PET/CT is shown in table. In general, the negative predictive value (NPV) was equivalent between CT and FDG PET/CT, whereas FDG PET/CT was better than CT in the specificity and accuracy. Conclusions: In patients with HNSCC, both CT and FDG PET/CT after chemoradiotherapy have a high NPV for excluding residual regional disease and avoiding unnecessary neck dissection. Although the NPV is similarly high, PET/CT has superior utility compared with CT because the number of false positive findings is less in PET/CT than CT. [Table: see text]
FcRn augments induction of tissue factor activity by IgG-containing immune complexes
Authors: Douglas B. Cines, Sergei Zaitsev, Lubica Rauova, Ann H. Rux, Victoria Stepanova, Sriram Krishnaswamy, Amrita Sarkar, M. Anna Kowalska, Guohua Zhao, Alan E. Mast, Laurence J. Blumberg, Keith R. McCrae, Mortimer Poncz, Jonathan J. Hubbard, Michal Pyzik, Richard S. Blumberg
Journal: Blood (2020)
THE ASSOCIATION BETWEEN SUBCLINICAL VOLUME OVERLOAD AND CARDIOVASCULAR OUTCOME AND ALL-CAUSE MORTALITY IN A HEALTHY THAI POPULATION
Authors: Phattararuethai Sabkaewyod, Prin Vathesatogkit, Piyamitr Sritara, Daruneewan Warodomwichit
Journal: Journal of the American College of Cardiology (2020)
HSR20-098: A Systematic Literature Review of First-Line (1L) Treatments for Patients With MGMT (O-6-Methylguanine-DNA Methyl Transferase) Methylated and Unmethylated Glioblastoma Multiforme (GBM)
Authors: Gautamjeet Singh Mangat, Roelien Postema, Shweta Takyar, Anagha Gogate, Alex Z. Fu
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-098: A Systematic Literature Review of First-Line (1L) Treatments for Patients With MGMT (O-6-Methylguanine-DNA Methyl Transferase) Methylated and Unmethylated Glioblastoma Multiforme (GBM)" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Optimizing the design and distribution of clinical trial information via handheld devices
Authors: V. Monaco, A. M. Arnold, B. Simon, K. S. McCarty, S. A. Jacobs
Journal: Journal of Clinical Oncology (2006)

6145 Background: The timely identification of available clinical trials by an oncologist for a patient represents a critical initial step in the research process. The challenges in supporting this step are threefold: (1) Large cancer centers may have more than 200 active clinical trials; (2) The accrual status of any particular clinical trial can change frequently; (3) Oncologists have limited time in their schedule to seek out clinical trial information. We hypothesized that delivering up-to-date clinical trial information directly to a handheld device would address the combination of these three challenges, and we utilized an iterative design process to refine the format and organization of this information. Methods: Web pages containing clinical trial information and optimized for a handheld display were created using an existing database and standard web development software. AvantGo software was utilized for transferring these web pages to handheld devices upon synchronization. Feedback on the initial design was obtained from four oncologists based in our community network locations. Two subsequent designs were developed based on both this feedback and encountered technical constraints. Results: Four major design changes emerged during our iterative design process. These changes included: (1) The organization of trial information based on network location; (2) The improvement of trial disease categories; (3) The shortening of trial titles; and (4) The inclusion of descriptive trial summaries for all trials. Conclusions: A demonstration of the handheld clinical trial information that is available to over 60 oncologists in our extended network will be provided. The merits of this approach as well as the lessons learned from our design process should be considered by other cancer centers seeking new methods for the distribution of clinical trial information. No significant financial relationships to disclose.
EARLY EXPERIENCE WITH THE EVOQUE MITRAL VALVE REPLACEMENT SYSTEM
Authors: John Webb, Mark Hensey, Neil Fam, Josep Rodes-Cabau, David Daniels, Robert Smith, Robert Boone, Jian Ye, Robert Moss, Wilson Szeto, Frank Silvestry, Mark Peterson, Geraldine Ong, Jean-Michel Paradis, Francois Dagenais, Jérôme Wintzer-Wehekind, Mathieu Bernier, Bilal Shafi, Deepu Nair, Molly Szerlip, Paul Grayburn, Konstantinos P. Koulogiannis, James Hermiller, Robert Guyton, Howard Herrmann
Journal: Journal of the American College of Cardiology (2020)
Bevacizumab (Bv) in non small cell lung cancer (NSCLC) patients ≥75 years old with pre-existing cardiovascular disease (CVD): Experience at a tertiary referral center.
Authors: Alexios S Strimpakos, Demetrios Vassos, Meropi Panagiotarakou, Konstantinos N. Syrigos
Journal: Journal of Clinical Oncology (2013)

e19087 Background: Bv is a novel anti-angiogenic agent used in many advanced solid tumours, including non-squamous NSCLC. In contrast to clinical studies where enrolled pts are fit, many elderly NSCLC pts suffer from co-morbidities and often have history of a CVD. Methods: Medical records of 2,672 pts diagnosed with NSCLC between 2001-2012 were screened. We identified and examined pts ≥75 yrs old treated with Bv, for their demographics, clinical data and treatment (Tx) details. We focused on those elderly pts with stable pre-existing cardiovascular disease. Results: 356/2672 NSCLC pts received Bv at any Tx line. 33/356 (9.2%) were ≥75 yrs old. Of those, 29 had various co-morbidities including 19 pts with stable CVD on medical Tx. In the 19 pts with CVD the male:female ratio was 17:2 and median age 76 yrs (range 75-86). 8/19 pts had impaired renal function. All pts were of Performance Status ECOG 0/1. Median number of Bv cycles was 5 (range 2-11). 17/19 pts experienced ≥1 side effects (11 epistaxis and haemoptysis, 5 proteinuria, 4 hypertension) which led to treatment discontinuation in 5 pts. No major/fatal adverse events were noted. 8/19 pts (42%) showed radiological partial response and 5 (19%) stable disease (total disease control rate 61%). Median survival from initiation of Bv till death/last follow up was 7 months (range 2-28, 95% CI 5.14-12.55). Conclusions: Treatment with Bevacizumab seems to be safe and effective in elderly NSCLC patients with controlled pre-existing cardiovascular disease and good PS. These patients might benefit from participation in clinical trials similarly to younger NSCLC patients.
Deregulated expression of Polycomb group genes in salivary gland adenoid cystic carcinoma
Authors: Hedvig Vekony, Frank Raaphorst, C. Leemans, Isaac Van der Waal, Elisabeth Bloemena
Journal: Cancer Research (2007)

182  Adenoid cystic carcinoma (ACC) is a relatively common malignant salivary gland tumor characterized by slow, yet invasive growth. This tumor has a poor long-term survival, mainly because of multiple recurrences and distant metastases, occurring in about 40-60% of patients even after 20 years. Currently, there are no parameters to reliably predict ACC tumor behavior. Polycomb group (PcG) proteins consist of two multimeric complexes. In normal healthy tissues, expression of their members is mutually exclusive. PcG genes are essential for maintenance of gene silencing after cell division, and have been linked to cell cycle regulation. Because abnormal PcG expression is linked to clinical behavior and loss of differentiation in various human tumors, we investigated their expression in neoplastic cells in ACC in relation to clinical behavior of these tumors. Furthermore, to investigate the functional role of genes which might be involved in ACC initiation and progression in vitro, RNAi experiments in an ACC cell line will be performed.  Paraffin-embedded material of 21 primary ACCs and 15 normal salivary glands were investigated using immunohistochemistry. ACCs were located in the major (n=19) and minor (n=2) salivary glands. Male-female ratio was 1:1.3, mean age at diagnosis 51.7 (25-81) and mean FUP was 72.8 (7-128) months. 48% of patients developed a recurrence and/or a metastasis and 29% of patients died of the disease.  Expression of cell cycle and proliferation markers (Mib-1, p53, p16, Cyclin D1) and PcG proteins (BMI-1, EZH2, MEL-18) was examined. Staining patterns were correlated to clinical data. Statistical analysis was performed using the Mann-Whitney U, Kaplan Meier and Cox regression analysis where appropriate. For the in-vitro experiments a myoepithelial cell line, named ACC3, was used.  P53, p16, Mib-1, Cyclin D1 and EZH2 expression was increased in ACC compared to normal tissue (p  In conclusion, expression of the two PcG complexes is deregulated in ACC. Negative regulation of p16 is not associated with expression of BMI-1. An algorithm based on Cyclin D1, EZH2 and p16 expression can possibly be used in the future to define patient subpopulations with favorable clinical outcome. RNAi experiments to demonstrate the functional role of EZH2 are in progress.
PATIENT-LEVEL, INSTITUTIONAL, AND TEMPORAL VARIATIONS IN IMAGING MODALITIES TO CONFIRM PULMONARY EMBOLISM
Authors: Ghazaleh Mehdipoor, David Jimenez, Laurent Bertoletti, Ángeles Figaldo, Juan Francisco Sanchez Muñoz-Torrero, Jose Gonzalez-Martinez, Ángeles Blanco-Molina, Miguel Ángel Aibar, Pierre-Benoit Bonnefoy, Ramin Khorasani, Martin R. Prince, Behnood Bikdeli, Manuel Monreal
Journal: Journal of the American College of Cardiology (2020)
BIO20-027: Comparison of Treatment Plans Feasible Through AI Enabled Multidisciplinary Online Tumor Board Solution vs. NCCN Based Clinical Decision Support System (CDSS)
Authors: Naresh Ramarajan, CS Pramesh, Gitika Srivastava, Vikas Ostwal, Anant Ramaswamy, Aju Mathew, Mahesh Goel, Supriya Chopra, BJ Sunil, Durgatosh Pandey, Rajendra A. Badwe, Bhawna Sirohi
Journal: Journal of the National Comprehensive Cancer Network (2020)

"BIO20-027: Comparison of Treatment Plans Feasible Through AI Enabled Multidisciplinary Online Tumor Board Solution vs. NCCN Based Clinical Decision Support System (CDSS)" published on 20 Mar 2020 by National Comprehensive Cancer Network.
IMPACT OF ROUTINE USAGE OF THE DETECT SCORE ON DISEASE SEVERITY AT DIAGNOSIS OF SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION: A SINGLE TERTIARY REFERRAL CENTER EXPERIENCE
Authors: Goutham Karuppiah, Emily Liu, Julian Neshewat, Amanda Wasserman, Susanne McDevitt, Victor Moles, Amber Young, Dinesh Khanna, Vallerie V. McLaughlin
Journal: Journal of the American College of Cardiology (2020)
HISTORY OF HEART FAILURE AS PREDICTOR FOR LENGTH OF STAY AND IN-HOSPITAL MORTALITY IN PATIENTS WITH ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE
Authors: Bassman Tappuni, Belal Kaseer, Ali Alkhayru, Gitanjali Lobo, Vahid Namdarizandi, Awfa Elabidin, Frank Harris, Stephanie Kovalchik, Sai Hanumanthu, Marshall Winner, Dominique Brandt, Jenni Steinbrunner, Kamal Shemisa
Journal: Journal of the American College of Cardiology (2020)
Effect of salmonella typhimurium A1-R on quiescent cancer cells that do not respond to standard chemotherapy.
Authors: Shuya Yano, Yong Zhang, Fuminari Uehara, Yukihiko Hiroshima, Shinji Miwa, Robert M. Hoffman, Ming Zhao
Journal: Journal of Clinical Oncology (2013)

e13576 Background: Quiescent cancer cells are a major impediment to treating solid cancer with chemotherapy, since in most tumors the majority of the cells are quiescent. Methods: The cell-cycle phase of each human MKN45 gastric cancer cell was imaged using a fluorescence ubiquitination cell cycle indicator (FUCCI). With FUCCI, quiescent cancer cells express mKusabira-Orange fluorescent protein (red) and proliferating cells express mAzami-Green fluorescent protein (green). FUCCI-labeled cancer cells in tumor spheres and subcutaneous tumor in nude mice were treated with Salmonella typhimurium A1-R. Results: Time-lapse confocal imaging showed that cancer cells in tumor spheres in serum-free culture become and remained quiescent. S. typhimurium A1-R infected and killed quiescent cancer cells in tumor spheres. In contrast, cytotoxic agents did not kill the quiescent cancer cells in the tumor spheres. S. typhimurium A1-R targeting of FUCCI-expressing subcutaneous tumors growing in nude mice resulted in the killing of quiescent cancer cells resistant to cytotoxic agents. Conclusions: S. typhimurium A1-R can kill quiescent cancer cells which suggests a new therapeutic paradigm potentially more effective than current therapeutics which are ineffective against quiescent cancer cells.
PREDICTORS OF REVASCULARIZATION IN WOMEN WITH ACUTE MYOCARDIAL INFARCTION AND SPONTANEOUS CORONARY ARTERY DISSECTION
Authors: Toshiaki Isogai, Anas Saad, Keerat Rai Ahuja, Mohamed M. Gad, Shashank Shekhar, Omar Abdelfattah, Manpreet Kaur, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial
Authors: N. P. Shah, P. Rousselot, R. Pasquini, N. Hamerschlak, J. Holowiecki, B. Gerard, D. Dejardin, H. Kantarjian
Journal: Journal of Clinical Oncology (2006)

6507 Background: High dose imatinib (800 mg/day) has been shown to have efficacy in a subset of CML patients with resistance to IM, although the durability of responses is not well-established. Dasatinib (BMS-354825) is a novel, highly potent, oral multi-targeted kinase inhibitor of BCR-ABL and SRC with activity against 18/19 imatinib resistant BCR-ABL mutants tested in vitro. Methods: START-R is a multicenter randomized (2:1 ratio) trial of D 70 mg twice daily (bid) and IM 800 mg/day in pts with CP-CML resistant to prior IM 400 to 600 mg/day. Cross-over was allowed for lack of response or intolerance (grade 3–4 non hematologic toxicity). D dose escalation to 90 mg bid was allowed for inadequate response at 12 wks, and dose reduction to 50 or 40 mg bid for drug toxicity. IM dose reduction to 600 mg/day was allowed. Evaluations consisted of weekly blood counts for the first 12 wks, bone marrow cytology and cytogenetics every 12 wks. The primary endpoint was major cytogenetic response (MCyR) rate at wk 12. Results: From February 2005 to November 2005, 150 pts were randomized of whom the first 36 pts (D 22, IM 14) are reported. Median age was 57 yrs, with 12 males and 24 females. Treatment groups were balanced with respect to CML characteristics; median time from initial diagnosis was 61 months for D and IM; prior interferon 64% and 79%; no prior CyR on IM 36% and 57%. BCR-ABL mutations were documented in 10 D pts and 1 IM pt. Dose reductions were required in 8 D pts and 1 IM pt. Complete hematologic response was documented in 21 D and 13 IM pts. MCyR rate at 12 wks was 45% for D and 21% for IM (7 complete for D and 1 for IM). With a 95% CI on the difference between D and IM was - 9.9 to +51.2. Two (9%) D and 11 (79%) IM pts crossed over for intolerance (1 D and 6 IM) or no MCyR (1 D and 5 IM). Grade 3–4 neutropenia or thrombopenia occurred in 8 and 9 dasatinib pts and in 8 and 2 IM pts. Most common grade 1–2 non-hematologic toxicities in D and IM groups were diarrhea (7 and 1 pts), nausea (7 and 7 pts), and facial/peripheral edema (8 and 7 pts). Conclusions: Dasatinib was effective in pts with CP-CML resistant to IM 400 to 600 mg/day. Preliminary data suggest that D is more effective and better tolerated than high dose IM. An updated analysis of all randomized pts will be presented. [Table: see text]
Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
Authors: Christian Hurtz, Gerald B. Wertheim, Joseph P. Loftus, Daniel Blumenthal, Anne Lehman, Yong Li, Asen Bagashev, Bryan Manning, Katherine D. Cummins, Janis K. Burkhardt, Alexander E. Perl, Martin Carroll, Sarah K. Tasian
Journal: Journal of Clinical Investigation (2020)

Children and adults with Philadelphia chromosome-like B cell acute lymphoblastic leukemia (Ph-like B-ALL) experience high relapse rates despite best-available conventional chemotherapy. Ph-like ALL is driven by genetic alterations that activate constitutive cytokine receptor and kinase signaling, and early-phase trials are investigating the potential of the addition of tyrosine kinase inhibitors (TKIs) to chemotherapy to improve clinical outcomes. However, preclinical studies have shown that JAK or PI3K pathway inhibition is insufficient to eradicate the most common cytokine receptor-like factor 2-rearranged (CRLF2-rearranged) Ph-like ALL subset. We thus sought to define additional essential signaling pathways required in Ph-like leukemogenesis for improved therapeutic targeting. Herein, we describe an adaptive signaling plasticity of CRLF2-rearranged Ph-like ALL following selective TKI pressure, which occurs in the absence of genetic mutations. Interestingly, we observed that Ph-like ALL cells have activated SRC, ERK, and PI3K signaling consistent with activated B cell receptor (BCR) signaling, although they do not express cell surface μ-heavy chain (μHC). Combinatorial targeting of JAK/STAT, PI3K, and "BCR-like" signaling with multiple TKIs and/or dexamethasone prevented this signaling plasticity and induced complete cell death, demonstrating a more optimal and clinically pragmatic therapeutic strategy for CRLF2-rearranged Ph-like ALL.
Elevated 68Ga-DOTATATE Activity in Fibrous Cortical Defect
Authors: Zhe Wen, Lin Zhang, Vandana Batra, Hongming Zhuang
Journal: Clinical Nuclear Medicine (2020)

FDG PET/CT was performed for staging in a 15-year-old adolescent girl with cholangiocarcinoma, which showed only mild activity in the tumor but more impressive FDG activity in right femoral fibrous cortical defect without any other hypermetabolic lesions elsewhere. Pathological examination of the resected cholangiocarcinoma revealed significant neuroendocrine differentiation, which lead to subsequent Ga-DOTATATE PET/CT study. Unexpectedly, the same femoral fibrous cortical defect also had increased Ga-DOTATATE activity.
Adequacy of biopsy samples for molecular testing in patients with non-small cell lung cancer.
Authors: Borys Hrinczenko, Subramony Subramonia-Iyer, Deng Zhang, Brian Olsen
Journal: Journal of Clinical Oncology (2012)

e21133 Background: Testing for a mutated EGFR gene has transformed the care of NSCLC. Although ASCO recommends EGFR mutation testing for cases of NSCLC, there have been no studies to assess adequacy of biopsy samples for molecular testing in non-trial settings. Methods: A retrospective chart review to identify patients diagnosed with NSCLC at our community hospital during 2010. A pathologist then reviewed the adequacy of archivedbiopsy material for EGFR mutation testing based on ASCO criteria (Eberhard, JCO 2008). Results: In 2010, 64 cases of NSCLC were diagnosed. Demographics:Thirty-six (56%) of the patients were male; median age was 69.5 years, 27 were current smokers, 33 were ex-smokers, median survival was 4.9 months. Histologic subtypes: squamous - 28 (44%), adenocarcinoma - 23 (36%), bronchoalveolar - 3 (5%), adeno with mixed bronchoalveolar - 2 (3%), large cell - 3 (5%), and large cell neuroendocrine - 2 (3%). Twenty-eight (44%) were considered adenocarcinoma. Staging: Stage I, II, III, IV - 18 (28%), 2 (3%), 13 (20%), 23 (36%). Eight (13%) had incomplete staging information. Biopsy material: transbronchial FNA in 23 (36%), CT-guided FNA in 13 (20%), definitive surgery in 18 (28%), other - 10 patients (15%). Imaging review: 29 central lesions (45%) and 35 (55%) peripheral. Specimen review: 45/64 (70%) were adequate for EGFR mutation analysis; Twenty cases (30%) were not. Among adenocarcinoma, 19/28 (68%) cases had adequate samples, but 9 (32%) did not. Conclusions: In this series, nearly one-third of all NSCLC cases, including adenocarcinoma, did not yield sufficient specimen from the first biopsy for EGFR mutation analysis. Newer molecular markers (EGFR, EML4-ALK) with targeted therapy such as erlotinib and crizotinib are available in NSCLC so adequate tissue sampling is imperative. Lack of satisfactory tumor tissue sampling may preclude mutation testing thereby denying these patients treatment with potential benefit and lower toxicity. This has implications for planned diagnostic investigations since an appropriate site must be biopsied so as to obtain an ample sample. Efforts to improve clinician awareness about adequate tumor sampling are needed and should be a top priority for multidisciplinary lung cancer teams.